A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209

Martin Schlumberger, Kate Newbold, Baktiar Hasan, Sandrine Marreaud, Samson Assele, Lisa Licitra, Patrick Schoffski, Sophie Leboulleux, Laura D Locati, Yann Godbert, Vincent Rohmer, Barbara Jarzab, Salvatore Domenico, Oliver Edgar Bechter, Sylvie Zanetta, Jaume Capdevila, Ellen Kapiteijn, Lars Bastholt

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Original languageEnglish
JournalJournal of Clinical Oncology
Volume36
Issue number15 Suppl.
Pages (from-to)6021
Number of pages1
ISSN0732-183X
DOIs
Publication statusPublished - May 2018
Event2018 ASCO Annual Meeting: Delivering discoveries: Expanding the reach of precision medicine - McCormick Place, Chicago , United States
Duration: 1. Jun 20185. Jun 2018
https://am.asco.org

Conference

Conference2018 ASCO Annual Meeting
LocationMcCormick Place
Country/TerritoryUnited States
CityChicago
Period01/06/201805/06/2018
Internet address

Cite this